key: cord-1034785-r911m080
authors: Tung-Chen, Yale; Gil-Rodrigo, Adriana; Algora-Martín, Ana; Llamas-Fuentes, Rafael; Rodríguez-Fuertes, Pablo; Marín-Baselga, Raquel; Martínez, Blanca Alonso; Rodríguez, Elena Sanz; Soriano, Pere Llorens; Ramos-Rincón, José-Manuel
title: The lung ultrasound “Rule of 7” in the prognosis of COVID-19 patients: results from a prospective multicentric study
date: 2021-09-04
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.07.012
sha: a2b4bbb6c14085675704e17dcff0b1b2e2e17d48
doc_id: 1034785
cord_uid: r911m080

Purpose: There is growing evidence regarding the imaging findings of coronavirus disease 2019(COVID-19) in lung ultrasound (LUS), however the use of a combined prognostic and triage tool has yet to be explored. To determine the impact of the LUS in the prediction of the mortality of patients with highly suspected or confirmed COVID-19.The secondary outcome was to calculate a score with LUS findings with other variables to predict hospital admission and emergency department (ED)discharge. Methods: Prospective study performed in the ED of three academic hospitals. Patients with highly suspected or confirmed COVID-19 underwent a LUS examination and laboratory tests. Results: A total of 228 patients were enrolled between March and September 2020. The mean age was 61.9 years (Standard Deviation - SD 21.1).The most common findings in LUS was a right posteroinferior isolated irregular pleural line (53.9%, 123 patients).A logistic regression model was calculated, including age over 70 years, C-Reactive Protein (CRP) over 70 g/L and a lung score over 7 to predict mortality, hospital admission and discharge from the ED. We obtained a predictive model with a sensitivity of 56.8% and a specificity of 87.6%, with an AUC of 0.813 [p<0.001]. Conclusions: The combination of LUS, clinical and laboratory findings in this easy to apply “rule of 7” showed excellent performance to predict hospital admission and mortality.

Eight months after the declaration of a global pandemic due to the novel coronavirus disease (COVID- 19) , with more than 36 million confirmed cases worldwide [1], high income countries continue to explore new tools for an improved diagnosis and treatment protocols while lower income countries are trying to adapt their hospital's capacity in order to prevent a system collapse [2] .

To date, over one million deaths have been reported globally, of which 55% were reported in the American continent [3] . Moreover, 8 out of 10 deaths reported in the United States have been in adults over 65 years old [4] . These facts enhance the critical need for an accessible, low cost diagnostic method and an easy-to-use tool for the early risk stratification in COVID-19 patients [5] . Lung ultrasound (LUS) qualifies for such a purpose, providing an evidence-based method which will aid to stratify patients depending on their risk of critical care need or death, hence conditioning their need to be admitted or transferred to a better equipped center [6] . Due to these characteristics, LUS seems an optimal tool for some special populations [7] , such as pregnant women, children and the elderly.

COVID-19 pandemic has been associated with high mortality rates, notably in patients older than 65 year with multimorbidity [8] , therefore it is pivotal to keep researching for practical, accessible and easy to use diagnostic and prognostic methods which could determine whether a patient will present complications, thus the need to be closely monitored. This could be a big change in daily practice in some nonhospital settings, such as nursing homes [9] .

Furthermore, an evidence-based LUS approach could be included in multi-criteria decision analysis systems in order to prioritize patients for hospital admission in lowincome areas with limited resources [10] .

To our best knowledge, the formulation of such an approach is in need for more research. We aimed to determine the impact of LUS, in combination with other clinical variables and laboratory parameters in the prediction of mortality, hospital admission and ED discharge of patients with highly suspected or confirmed coronavirus disease (COVID-19). 

This was a prospective study performed in the emergency department (ED) of three academic hospitals, conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of each University Hospital involved.

Informed consent was obtained from each enrolled patient.

Patients admitted to the ED with a clinical suspicion of COVID-19 (temperature above 37.2ºC, acute respiratory symptoms, gastrointestinal symptoms, or fatigue) requiring Xray for evaluation were included. We excluded patients <18 years or those who declined to participate. A sample of patients who met these inclusion criteria were enrolled and prospectively studied.

We collected the clinical data directly by an individual review of the patient's electronical clinical records from the hospital's database (DXC-HCIS-Healthcare J o u r n a l P r e -p r o o f international normalized ratio, partial thromboplastin time, fibrinogen]) were obtained from various hospital data management systems, and information regarding treatment provided during hospital stay was collected from the electronic prescription system.

Both patient selection and assessment were performed by the treating physician, who notified the sonographers of a potential study subject. To guarantee the sonographers were blinded, they did not have access to the patients' data.

Patients underwent chest X-ray or chest Computed Tomography (CT), performed by fellowship-trained radiologists together with a LUS, performed by ultrasound fellowship-trained emergency physicians according to the American College of Emergency Physicians ultrasonographic guidelines, with more than 10 ultrasound exams performed per week, and 5 years of experience in performing and interpreting LUS [11] performed all the ultrasound exams. Therefore, an opportunity sampling method was implemented for patient selection.

Participants underwent ultrasonographic measurement of the inferior vena cava (IVC) and a focused cardiac ultrasound (FOCUS). The ultrasound examination of the IVC poses the necessity to consider possible confounding factors. There are situations when the decrease of IVC diameter is not related to progression to hypovolemia, and may be linked to increased abdominal pressure, or an abnormal inspiratory effort. Some specific cardiac and pulmonary conditions determining an obstacle to the venous return or in alveolar hyperinflation, and so on; so, it is essential to consider the clinical settings.

A LUS was performed following a 11-zone protocol ( Figure 1 ) [12] . The sonographers were blinded to the patient's past medical history, vital signs, symptoms, laboratory measurements and therapy. The results of the ultrasound were J o u r n a l P r e -p r o o f recorded in the patient's medical history, and this information was available to the treating physician, who adjusted the therapy based on these findings. However, the analytical and X-ray request depended on the clinical criteria of the treating physician, who in no case was previously aware of the ultrasound results. Only in the case of pregnant women was this information provided to avoid taking a chest X-ray.

The main purpose of this study was to describe and correlate the LUS findings of the disease in patients with COVID-19 admitted to the ED with prognosis. The primary outcome was to determine the impact of the LUS and mortality of patients with highly suspected or confirmed coronavirus disease (COVID-19). The secondary outcome was to calculate a score with LUS findings in combination with other variables (laboratory markers, physical exam, demographics) to predict Hospital admission and emergency department (ED) discharge.

We defined a confirmed case as any patient with clinical symptoms and positive RT-PCR, and a high suspicion case as any patient with negative RT-PCR but compatible clinical symptoms and typical X-ray, CT scan or LUS.

We developed a numeric Lung Score based on the pathological findings in each lung echographic area, taking as a reference Soldati et al. score [15] . Although we differentiated eleven lung echographic areas (figure 1) and gave each pathological Our aim was to determine the impact of LUS, in combination with other clinical variables and laboratory parameters in the prediction of mortality, hospital admission and ED discharge of patients with highly suspected or confirmed COVID-19.

A total of 228 patients were enrolled between March and September 2020 (Fig. 3) . The Table 1 ).

In the group of patients who died, the mean lung score was 13.9 (SD 7.1), CRP of 122.8 mg/dL (SD 102.3) and age of 81.8 years (SD 12.9) in comparison with a lung score of 9.1 (7.3), CRP of 43.3 (SD 75.9) and age of 57.9 (SD 20.1) in the group of patients who survived (p < 0.001).

In the group of patients were admitted to the hospital, the mean lung score was 12.9 (SD 6.9), CRP of 86.4 mg/dL (SD 96.6) and age of 70.2 years (SD 18.3) in comparison with a lung score of 6.0 (6.2), CRP of 15.2 (SD 42.4) and age of 51.0 (SD 19.4) in the group of patients who were discharged from the ED (p < 0.001).

All the included patients underwent a LUS study, and almost all of them had a chest Xray (see Table 2 ). The most frequent pattern in the chest X-ray were an interstitial 

The primary goal of this investigation was to describe and correlate the LUS findings of the disease in patients with COVID-19 admitted to the ED.

Setting the Lung Score threshold at 7 points, we found a sensitivity of 76.3% and a specificity of 48.4% (p = 0.005), the specificity increased to 63.7% but with a decrease of the sensitivity to 63.7% (p = 0.002) if the Lung Score was set at 10 points.

An analysis of receiver operating characteristic curves (Figure 3 ) showed the area under the curve [AUC] for age over 70 years, CRP over 70 g/L and Lung score over 7.

We generated a logistic regression model using age over 70 years, CRP over 70 g/L and Lung score over 7 to predict mortality, hospital admission and discharge from the ED.

Globally, using these three parameters (age over 70 years, CRP over 70 g/L and Lung Score over 7) we obtained a predictive model with a sensitivity of 56.8% and specificity of 87.6%, with an AUC of 0.813 (p < 0.001) to predict mortality. A sensitivity of 88.5% and specificity of 53.3%, with an AUC of 0.769 (p < 0.001) to predict hospital admission, and a sensitivity of 61.5% and specificity of 89.2%, with an AUC of 0.813 (p < 0.001) to predict discharge from ED. (Fig. 4) Our investigation aimed to create a score which could correlate with mortality, so it could be put into practice in non-hospital settings and lower income areas and help prioritize which patients needed transferring to a medical facility for closer monitoring.

Some studies have used lung ultrasound as a triage for symptomatic patients outside hospital settings [15] .

The combined score we produced includes three factorsage, CRP and LUS findingswhich could be obtained in many settings. Regarding age, it is well known that it is a negative prognostic factor in COVID-19 patients, rising to a 32,5% mortality rate in severe cases [19] . Nevertheless, age only is a lacking method of triage, for the older global population greatly exceeds the health systems' capacity.

Moreover, Chinese studies CRP has been found to be an independent predictor of adverse outcomes with a high sensitivity and specificity [20] . Elevation of CRP has also been positively correlated with chest CT findings and severity of COVID-19. [21] Concerning LUS examination, some authors claim it can replace the stethoscopewhich is challenged as efficient in viral pneumonias -, a way to guarantee both patients' right to be thoroughly examined and the health care providers safety [22] .

There is growing literature suggesting LUS as safe and easily accessible tool, which helps in early correct diagnosis, appropriate management and a positive correlation with prognosis [23] [24] [25] [26] To the best of the authors' knowledge, this is the first time that age, CRP and LUS findings have been combined in a score which can predict hospital admission and mortality. We believe this approach is a simple and reproducible one, which can be put The findings in our study should be interpreted with its limitations. First, the sample size was a medium one, and it included patients with sufficient severity of symptoms to consult in the ED. Further studies should explore the role of combined Scores outside a Hospital setting and with a greater sample size. Second, our study did not take into account other factors (eg, therapy against COVID-19 or symptomatic therapy) in the association between our score and hospital admission rate and mortality. Thirdly, in a pandemic situation, the high prevalence of respiratory infection attributed to SARS-CoV-2 could have generated a bias because ultrasound findings are not apt to determine etiology, so all findings compatible with COVID-19 were considered as such. Another limitation is the chance of misdiagnosis, since there might be other diseases mimicking COVID-19 or even more, the performance of the RT-PCR is not 100% accurate, this could be a challenge to interpret the LUS findings. This limitation was minimized given the patients were followed-up by reviewing their electronic history, and any complications were recorded. Moreover, LUS findings might become paramount in negative or indeterminate PCR patients, for it could indicate a change in patient diagnosis or therapy [27] . On the other hand, the treating physician knows the LUS findings; so this could modified the management. Finally, our score needs an experienced sonographer to evaluate LUS findings. The combination of LUS, clinical and laboratory findings in this easy to apply "rule of 7" (LUS score >7, age >70 year-old and CRP >70 g/L) showed a good to excellent performance to predict hospital admission and mortality. Ethics approval: We certify that this research was conducted in conformity with ethical principles of our institution. This study was carried out in strict compliance with the principles of the Declaration of Helsinki.

Under the exceptional circumstances generated by the COVID-noninterventional and retrospective nature of the project, the requirement that written patient consent be obtained to be included in the study was waived. All patients were codified by investigators of the participating centers before entering their data into the general database, thereby ensuring patient anonymity to investigators analyzing the database. This study was carried out in strict compliance with the principles of the Declaration of Helsinki. The authors designed the study, gathered and analyzed the data, vouched for the data and analysis, wrote the article, and decided to publish.

Data Access and Responsibility: The principal investigator, Yale Tung Chen, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

J o u r n a l P r e -p r o o f Lung Score > 10 93 (40.8)

WHO. Coronavirus disease pandemic. Im internet

Accessed on 28th of October

Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide

CDC. Older Adults. 2020. Im Internet

Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study

A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study

How to perform lung ultrasound in pregnant women with suspected COVID-19

Point-ofcare chest ultrasonography as a diagnostic resource for COVID-19 outbreak in nursing homes

Prognostic Value of Lung Ultrasonography in Older Nursing Home Residents Affected by COVID

Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage

Ultrasound Guidelines: Emergency, Point-of-Care and Clinical Ultrasound Guidelines in Medicine

Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress

What´s new in lung ultrasound during the COVID-19 pandemic

International evidence-based recommendations for point-of-care lung ultrasound

Is there a role for lung ultrasound during the COVID-19 pandemic?

Lung Ultrasound May Support Diagnosis and Monitoring of COVID-19 Pneumonia

Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment

Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity -United States

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Prognostic value of Creactive protein in patients with COVID-19

C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early

COVID-19 outbreak: less stethoscope, more ultrasound

The ultrasound guided triage: a new tool for prehospital management of COVID-19 pandemic

Capacidad diagnóstica de la ecografía clínica pulmonar en pacientes con COVID-19

Report from an International Webinar

Point-of-care ultrasonography in the initial characterization of patients with COVID-19

Gender (female) -N (%)

ARB: Angiotensin receptor blockers; E:D: Emergency Department; LDH: Lactate dehydrogenase; NT-ProBNP: N-terminal pro-brain natriuretic peptide; PCR: Polymerase chain reaction